Drug Delivery

Defence Therapeutics (DTCFF) appointed Dr. Amie Phinney to its Board of Directors. Dr. Phinney, previously a Strategy and Business Advisor, will now contribute to corporate governance and value creation as the company advances its drug-delivery platform. Defence granted her 100,000 stock options, exercisable at $0.75 per share. This appointment aims to enhance the company’s leadership and capitalize on Dr. Phinney’s pharma and biotech expertise, potentially impacting treatment landscapes.